Construction and immune efficacy of recombinant Lactobacillus casei expressing OmpAI of Aeromonas veronii C5–I as molecular adjuvant

2021 ◽  
pp. 104827
Author(s):  
Ze Lin-Zhao ◽  
Bin Tong-Yang ◽  
Yang Yi-Xuan ◽  
Song Ning-Guo ◽  
Dong Xing-Zhang ◽  
...  
2020 ◽  
Vol 141 ◽  
pp. 103918
Author(s):  
An-Qi Ju ◽  
Shu-bao Yang ◽  
Hai-Peng Zhang ◽  
Xin Ma ◽  
Dong-Xing Zhang ◽  
...  

2019 ◽  
Vol 21 (1) ◽  
pp. 33
Author(s):  
Jia-Xin Tian ◽  
Yuan-Huan Kang ◽  
Guo-Sheng Chu ◽  
Hong-Jian Liu ◽  
Yi-Di Kong ◽  
...  

Aeromonas veronii is a pathogen capable of infecting humans, livestock and aquatic animals, resulting in serious economic losses. In this study, two recombinant Lactobacillus casei expressing flagellin A (FlaA) of A. veronii, Lc-pPG-1-FlaA (surface-displayed) and Lc-pPG-2-FlaA (secretory) were constructed. The immune responses in fish administered with recombinant L. casei were evaluated. The two recombinant L. casei were orally administered to common carp, which stimulated high serum IgM and induced higher ACP, AKP, SOD and LYZ activity. Using qRT-PCR, the expression of IL-10, IL-8, IL-1β, TNF-α and IFN-γ in the tissue of fish immunized with recombinant L. casei was significantly (p < 0.05) upregulated, which indicated that recombinant L. casei could activate the innate immune system to trigger the cell immune response and inflammatory response. Furthermore, recombinant L. casei was able to survive the intestinal environment and colonize in intestine mucosal. The study showed that after being challenged by A. veronii, fish administered with Lc-pPG-1-FlaA (70%) and Lc-pPG-2-FlaA (50%) had higher survival rates compared to Lc-pPG and PBS, indicating that recombinant L. casei might prevent A. veronii infection by activating the immune system to trigger immune responses. We demonstrated that flagellin as an antigen of vaccine, is acceptable for preventing A. veronii infection in fish. The recombinant L. casei expressing FlaA may be a novel mucosal vaccine for treating and controlling A. veronii.


2019 ◽  
Vol 133 ◽  
pp. 103552 ◽  
Author(s):  
Lei Zhang ◽  
Zhenxing Li ◽  
Ying Li ◽  
Jiaxin Tian ◽  
Kaixiang Jia ◽  
...  

Parasite ◽  
2020 ◽  
Vol 27 ◽  
pp. 26 ◽  
Author(s):  
Yu-Chao Zhu ◽  
Yong He ◽  
Jian-Fa Liu ◽  
Jia Chen

Toxoplasma gondii is a threat for immunocompromized individuals, and no treatment is available for enhancing immunity against infection. Molecular adjuvants may improve the efficacy of DNA vaccine-induced T cell immunity. Here, we report that cocktailed DNA immunization with ROP5 and ROP18 boosted immune responses induced by a single DNA immunization with ROP5 or ROP18, but also that co-administration of molecular adjuvant IL-33 enhanced immune efficacy induced by this cocktailed DNA vaccination. These improved immune responses were characterized by higher Toxoplasma-specific IgG2a titers, Th1 responses associated with the production of IFN-γ, IL-2, IL-12, as well as cell-mediated activity with higher frequencies of CD8+ and CD4+ T cells. More importantly, this enhanced immunity has the ability to confer remarkable protection against a high dose lethal challenge of the T. gondii RH strain and thus against chronic infection with the T. gondii PRU strain. These data show that IL-33 is a promising immunoadjuvant to facilitate humoral as well as cellular immunity in a vaccine setting against T. gondii, and suggest that it should be evaluated in strategies against other apicomplexan parasites.


2009 ◽  
Vol 47 (05) ◽  
Author(s):  
C Kamhuber ◽  
S Hörist-Kollmann ◽  
A Rek ◽  
G Eckhardt ◽  
A Zauner ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document